Skip to main content

Table 1 Drugs, doses and therapeutic regimens applied in the presented studies

From: 1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis

Experimental model

Drug

Route of administration

Dose

Treatment regimen

Experimental metastasis (Fig. 1)

1-MNA

Per os in drinking water

100 mg/kg/day

Treatment initiated 7 days prior cancer transplantation and continued to the end of the experiment

1,4-DMP

Spontaneous metastasis (single drug treatment) (Fig. 2)

1-MNA

Per os in drinking water

100 mg/kg/day

Continuously from the 7th day of the experiment to the end of the experiment

1,4-DMP

Matrigel plugs (Fig. 3)

1-MNA

Per os in drinking water

100 mg/kg/day

Continuously starting from the day of matrigel plugs transplantation

1,4-DMP

Cyclophosphamide

intraperitoneally

25 mg/kg/day

On days 0, 3, 5

Spontaneous metastasis (combined treatment) (Fig. 4 and 5)

1-MNA

Per os in drinking water

100 mg/kg/day

Continuously from the 1st day of the experiment to the end of the experiment

1,4-DMP

Cyclophosphamide

Intraperitoneally

25 mg/kg/day

From the 7th day of the experiment, 3 times each week